SIShafiul Islam

Shafiul Islam

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Shafiul Islam has a total of 10 co-authors. Here are the top co-authors by number of shared publications:

  • Akihito Nishiyama

    Department of Bacteriology, Graduate School of Medical and Dental Sciences, Niigata University, 757 Ichibancho, Asahimachi-dori, Chuo-Ku, Niigata, 951-8510, Japan

    1 shared publication
  • Amina Kaboso Shaban

    Department of Bacteriology, Graduate School of Medical and Dental Sciences, Niigata University, 757 Ichibancho, Asahimachi-dori, Chuo-Ku, Niigata, 951-8510, Japan

    1 shared publication
  • Atsuki Takeishi

    Department of Bacteriology, Graduate School of Medical and Dental Sciences, Niigata University, 757 Ichibancho, Asahimachi-dori, Chuo-Ku, Niigata, 951-8510, Japan

    1 shared publication
  • Satoshi Iwano

    Institute for Tenure Track Promotion, University of Miyazaki, Miyazaki, Miyazaki, 889-2192, Japan

    1 shared publication
  • Sohkichi Matsumoto

    Department of Bacteriology, School of Medicine, Niigata University, Niigata, Japan

    1 shared publication
  • Takasuke Fukuhara

    Department of Virology, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan

    1 shared publication

Latest Publications

  • Open Access

    Real-time bioluminescence imaging of mycobacteria with Akaluc: a novel method for monitoring drug efficacy

    by Shafiul Islam, Atsuki Takeishi, Yoshitaka Tateishi, Akihito Nishiyama, Yuriko Ozeki, Yutaka Yoshida, Amina Kaboso Shaban, Takeshi Annoura, Satoshi Iwano, Takasuke Fukuhara, et al.

    Tuberculosis (TB) still threatens human life despite the availability of childhood vaccination and modern treatment regimens due to the emergence of tuberculosis with extended resistance profiles. The mouse active TB model remains the gold standard for evaluating anti-TB drugs and vaccines. However, in vivo experiments raise ethical concerns and are time-consuming. We established an Akaluc-based bioluminescence platform to enable rapid drug screening in culture media and THP‑1 cells. Codon-optimized Akaluc expression in mycobacteria was accomplished by assortment of vectors and promoters. Bioluminescence kinetics were evaluated in culture media and THP‑1 cells with or without drug treatment, and optimized by adjusting time points and substrate concentrations. TokeOni at a concentration of 10 nM/100 µL produced the highest bioluminescence compared to other tested concentrations and substrates. Among the tested promoter-plasmid constructs, the Ag85B promoter in pMV261 generated the strongest bioluminescence in Mycobacterium smegmatis and Mycobacterium bovis. Bioluminescence fluctuated with bacterial growth, peaking during the log phase and gradually declining during the stationary phase. A positive correlation was observed between bioluminescence and CFU reduction in vitro upon treatment with sensitive drugs.